Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Arizona Off-Label Policy Update | OpenP…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of ArizonaPolicy N/A

    OFF-LABEL USE OF NON-CANCER MEDICATIONS

    Customize your policy alerts

    Sign up for all blue cross blue shield - arizona policy alerts

    Know when blue cross blue shield - arizona releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Pharmacy Coverage Guideline governs medical-necessity and prior-authorization review for non-cancer uses of FDA-approved medications that are not FDA-approved for the requested indication. It applies to Commercial and/or Marketplace members and excludes Federal Employee Program, Medicare Advantage, Medicaid, and out-of-state Blue Cross and/or Blue Shield members.

    Policy Summary
    PayerBlue Cross Blue Shield of Arizona
    PolicyOFF-LABEL USE OF NON-CANCER MEDICATIONS
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior-authorization request with chart notes, laboratory workup, and supporting documentation, signed by the prescribing provider.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsInitial therapy approval duration
    2+Formulary alternatives required
    3Generic equivalents for brand-specific requests
    2Peer-reviewed articles supporting safety and effectiveness

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsContinuation approval duration

    Coverage Criteria

    Initial Therapy

    Covered when all applicable initial-therapy requirements are met.

    Initial therapy requirements

    • Acceptable authoritative evidence: Evidence supporting the off-label use is provided from one acceptable authoritative source, including AHFS with narrative text of supportive; IBM Micromedex DrugDex meeting the specified recommendation, evidence, and efficacy thresholds; Elsevier Gold Standard Clinical Pharmacology with narrative text of supportive; Wolters Kluwer Lexi Drugs listing the use as off label with evidence level A; or another authoritative reference identified by the Secretary of the United States Department of Health and Human Services.
    • Peer-reviewed evidence: At least two articles from major peer-reviewed professional medical journals support safety and effectiveness for the exception.At least 2 articles

    Brand-Specific Criteria

    For brand-specific requests when generic equivalents are available:

    Brand-specific requirement: The member has failure, contraindication, or intolerance with three generic equivalents, if available, for at least three months each.3 generic equivalents; at least 3 months each

    Any failure, contraindication, or intolerance to the generic drugs should be reported to the United States Food and Drug Administration.

    Continuation Therapy

    Continuation therapy is approved when all applicable requirements are met.

    Continuation therapy criteria

    • Clinical response: There is no evidence of disease progression and there is documented efficacy, disease stability, and/or improvement.
    • Adherence to the prescribed therapy regimen has been documented.
    • Brand-specific criteria when applicable: The patient has experienced failure, contraindication, or intolerance with three generic equivalents, if available, for at least three months each.3 generic equivalents; at least 3 months each

      Failures, contraindications, or intolerances to generic drugs should be reported to FDA MedWatch.

    • Safety:

    Experimental or Investigational Off-Label Use

    An off-label exception request is considered experimental or investigational when any one or more of the following criteria are met.

    Experimental or investigational criteria

    • Regulatory approval: The medication lacks final approval from the appropriate governmental regulatory bodies, such as the FDA.
    • Evidence of health outcomes: Scientific evidence is insufficient to permit conclusions concerning the effect on health outcomes.
    • Net health outcome: Evidence is insufficient to support improvement of the net health outcome.
    • Comparison with established alternatives: Evidence is insufficient to support improvement of the net health outcome as much as, or more than, established alternatives.

    Coverage requires that no FDA-labeled contraindication applies to the requested drug. The request must also have no significant product-label exclusions, including warnings or precautions related to kidney dysfunction, hepatic dysfunction, or other relevant medical conditions, and no significant interacting drugs.

    Coverage requires that no applicable benefit or contract exclusion applies to the requested medication and off-label use.

    Initial Off-Label Therapy

    Initial Off-Label Therapy

    Initial therapy is covered when all applicable criteria are met.

    Initial off-label therapy

    • Acceptable evidence: Evidence supporting the off-label use is provided from an acceptable authoritative source identified in the policy, or at least two articles from major peer-reviewed professional medical journals support safety and effectiveness for the exception.At least 2 peer-reviewed articles when relying on journal evidence

    Continuation and Renewal Therapy

    Renewal Therapy

    Renewal therapy is approved when all applicable continuation requirements are met.

    Renewal therapy requirements

    • Clinical benefit: There is no evidence of disease progression and there is documented efficacy, disease stability, and/or improvement.
    • Adherence to the prescribed therapy regimen has been documented.
    • Generic trials for brand-specific requests: The patient has experienced failure, contraindication, or intolerance with three generic equivalents, if available, for at least three months each.3 generic equivalents; at least 3 months each

      Failures, contraindications, or intolerances to generic drugs should be reported to FDA MedWatch.

    Required Medication Trials

    StepMedication requirementRequired outcome
    1Try two or more other FDA-approved medications on the formulary before the requested off-label medication.Failure, contraindication, or intolerance
    StepMedication requirementRequired outcomeMinimum trial duration
    2For a brand-specific request, try three generic equivalents when available.Failure, contraindication, or intoleranceAt least three months for each generic equivalent
    StepMedication requirementRequired outcomeMinimum trial duration
    1For brand-specific criteria, try three generic equivalents when available.Failure, contraindication, or intoleranceAt least three months each

    Prior Authorization and Documentation

    Prior Authorization

    Complete Prior Authorization Request

    Submit a complete prior-authorization request for the requested medication. The prescribing provider must sign the form and include all required supporting information.

    • Complete the request form.
    • Include chart notes, laboratory workup, and any other supporting documentation.
    • Fax to BCBSAZ Pharmacy Management at (602) 864-3126 or email Pharmacyprecert@azblue.com.
    Step Therapy

    Try Formulary Alternatives First

    Before requesting the off-label medication, document failure, contraindication, or intolerance to at least two other FDA-approved formulary medications.

    • Required history must address two or more formulary alternatives.
    • Document the specific failure, contraindication, or intolerance for each alternative.

    Policy Background

    This guideline addresses the use of FDA-approved medications for non-cancer conditions outside their FDA-approved indications. Coverage review considers evidence supporting safety and effectiveness, appropriate dosing, prior use of formulary alternatives, patient-specific safety factors, and documentation supporting medical necessity.

    Definitions and References

    FDA-approved indication
    Also known asLabeled indication
    DefinitionA specified medication use reviewed and approved by the FDA for marketing
    Approval basisAdequate, well-controlled clinical trials documenting safety and effectiveness
    Off-label use
    DefinitionUse of an FDA-approved medication for conditions, indications, or circumstances other than those approved by the FDA
    Also known asUnapproved use or unlabeled use
    Scope
    Policy Summary
    PayerBlue Cross Blue Shield of Arizona
    PolicyOFF-LABEL USE OF NON-CANCER MEDICATIONS
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior-authorization request with chart notes, laboratory workup, and supporting documentation, signed by the prescribing provider.
    SourceLink
    On This Page
    Coverage CriteriaInitial Off-Label TherapyContinuation and Renewal TherapyRequired Medication TrialsPrior Authorization and DocumentationPolicy BackgroundDefinitions and References
    There are no new contraindications or significant adverse drug effects, no significant exclusions to use under the product label such as kidney or hepatic dysfunction warnings or precautions, and no significant interacting drugs.
  1. Additional requirements: There are no benefit or contract exclusions that apply.
  2. Documentation: Chart notes, supporting clinical documentation showing improvement in the indication, and laboratory values confirming safe use are provided.
  3. Non-investigational setting: Evidence is insufficient to support improvement outside the investigational setting.
  4. Safety: There are no new contraindications or significant adverse drug effects, no significant product-label exclusions such as kidney or hepatic dysfunction warnings or precautions, and no significant interacting drugs.
  5. Documentation: Chart notes, supporting clinical documentation demonstrating improvement in the treated indication, and laboratory values confirming safe use under the applicable safety criteria are provided.
  6. Step Therapy

    Generic-Equivalent Prerequisite

    For a brand-specific request, document failure, contraindication, or intolerance to three generic equivalents when available, with each generic tried for at least three months.

    • Report any failure, contraindication, or intolerance to the generic drugs to the U.S. Food and Drug Administration (FDA).
    Step Therapy

    Trial of Generic Equivalents

    Continuation of a brand-specific medication requires documented failure, contraindication, or intolerance to three available generic equivalents, each used for at least three months.

    • Report any failure, contraindication, or intolerance to the generic drugs to the FDA.

    Unsupported block type: documentation

    Documentation Required

    Clinical Rationale and Evidence

    Provide the diagnosis and treatment plan, explain the rationale for the off-label use, and document an appropriate dose and supporting evidence.

    • Dose must be consistent with manufacturer recommendations or FDA-approved labeling.
    • Support the request with an accepted authoritative drug reference or at least two articles from major peer-reviewed professional medical journals addressing safety and effectiveness.
    • Accepted references include AHFS with a “supportive” narrative; IBM Micromedex DrugDex meeting the specified recommendation, evidence, and efficacy criteria; Elsevier Gold Standard Clinical Pharmacology with a “supportive” narrative; Wolters Kluwer Lexi-Drugs listing “off label, evidence level A”; or another authoritative reference identified by the U.S. Department of Health and Human Services.
    Documentation Required

    Document Alternative Medication History

    Document the member’s complete alternative-medication history, including the required failures, contraindications, or intolerances before requesting the off-label drug.

    • Address at least two FDA-approved formulary alternatives.
    • For brand-specific requests, address three generic equivalents when available, each used for at least three months.
    • Identify the clinical reason each alternative could not be used or was unsuccessful.
    Documentation Required

    Continuation Therapy Documentation

    For continuation therapy, submit records showing improvement in the treated indication and laboratory values confirming that continued use is safe.

    • Chart notes
    • Supporting clinical documentation with evidence of improvement
    • Laboratory values confirming safe use under the applicable safety criteria
    Prior Authorization

    Drug and Indication Eligibility

    The requested medication must be FDA approved for at least one indication and requested for a non-cancer indication that is not FDA approved.

    • The request must be for a non-cancer off-label use.
    • The drug must have FDA approval for at least one other indication.
    Denial Risk

    Insufficient Evidence or Alternatives

    Requests may be denied when the submitted evidence is insufficient or when required formulary and generic alternatives have not been adequately tried or documented.

    • Provide qualifying evidence of safety and effectiveness for the off-label use.
    • Document failure, contraindication, or intolerance to the required formulary alternatives.
    • Do not rely on unsupported clinical rationale or incomplete alternative-therapy history.
    Denial Risk

    Safety Exclusion

    Confirm that the requested medication can be used safely for the member and does not conflict with labeling or other medications.

    • No FDA-labeled contraindication may apply.
    • No significant product-label exclusion may apply, including relevant kidney or liver conditions, warnings, or precautions.
    • No significant interacting drugs may be present.
    Denial Risk

    Benefit Exclusion

    Verify that no member benefit or contract exclusion applies to the requested service.

    • A benefit or contract exclusion is a basis for denial even when other clinical criteria are met.
    Denial Risk

    Samples Are Not Treatment Evidence

    Do not use patient samples to establish an initial treatment course, justify continuation therapy, or demonstrate an adequate trial and failure.

    • Samples do not satisfy the required treatment history or alternative-therapy documentation.
    Denial Risk

    Experimental or Investigational Use

    An off-label exception is considered experimental or investigational when any listed criterion is met, and the request may be denied.

    • The drug lacks final approval from the appropriate governmental regulatory body, such as the FDA.
    • Scientific evidence is insufficient to draw conclusions about health outcomes.
    • Evidence is insufficient to support improvement in the net health outcome.
    • Evidence is insufficient to show improvement equal to or greater than established alternatives.
    • Evidence is insufficient to support improvement outside the investigational setting.
    Includes uses ranging from completely unstudied uses to scientifically investigated uses without formal FDA approval
    Final FDA marketing approval
    DefinitionFinal FDA marketing approval for purposes of this policy
    New Drug ApplicationNDA
    Abbreviated New Drug ApplicationANDA
    Biologic License ApplicationBLA
    Compendium
    DefinitionA comprehensive listing of FDA-approved drugs and biologics
    Drug informationIncludes a summary of how each drug works in the body and information about proper dosing
    Clinical-use informationIdentifies whether a drug is recommended or endorsed for treating a specific disease
    FDA MedWatch
    ReferenceU.S. Food and Drug Administration MedWatch Forms for FDA Safety Reporting
    PurposeUsed for reporting safety issues involving generic drugs
    Applicable circumstancesReferenced when failure, contraindication, or intolerance to a generic drug is identified